Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for...
-
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies …………..… TORONTO and CAMBRIDGE, Mass., Jan. 25,...
-
TORONTO and CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of precision...
-
TORONTO and CAMBRIDGE, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF)...
-
TORONTO and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for...
-
TORONTO and CAMBRIDGE, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases,...
-
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for...
-
TORONTO and CAMBRIDGE, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for...
-
TORONTO and CAMBRIDGE, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for...
-
Presentation highlights the use of ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO and CAMBRIDGE,...